Sign in
CompletedNo phase

Impact of Prior SGLT2 Inhibitors Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury

Key facts

Who runs it
University of Jazan
Where
Saudi Arabia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
664 people enrolled
Started
1 Apr 2024
Ended
1 Mar 2025
Type of study
Observational, 2 groups
Record updated
30 March 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • All adult (≥ 18 year) patients who were admitted to ICU with sepsis syndromes (sepsis or septic shock), according to sepsis-3 definition

Who cannot take part

  • Renal transplant or tumor
  • Missing data
  • Solitary kidney
  • Established CKD
  • Obstructive uropathy
  • Renal artery stenosis
  • Pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of this study is to investigate whether using SGLT2i may be associated with decreased incidence of sepsis-induced AKI or not.

The 2 groups in the trial

  • SA-AKI Group

    Patients diagnosed with sepsis syndromes (sepsis or septic shock) and AKI according to sepsis-3 definition and KDIGO criteria, respectively

  • No AKI group

    Patients diagnosed with sepsis syndromes (sepsis or septic shock) and AKI according to sepsis-3 definition

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Prior Sodium-Glucose Co-Transporter 2 Inhibitor Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury
Record updated
30 March 2025